Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery
June 24, 2022
Speaker: John Charpentier, Ph.D, Business Development Manager, Biocytogen Boston Introduced Biocytogen’s highly immunodeficient B-NDG mouse model Discussed our latest, next-generation B-NDG-derived models, such as the B-NDG β2m KO, B-NDG HLA-A2.1, and B-NDG hSIRPα/hCD47 models Described how B-NDG models recapitulate critical aspects of human biology, making them a powerful tool for biomedical research
Generation and discovery of high affinity antibodies
May 2, 2022
Speaker: Li Hui, MD, Ph.D. Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston Introduced Biocytogen’s Antibody Discovery Service capabilities, which includes multiple screening technologies and accommodates antibody discovery needs for multiple species, including human, mouse, and rat. Provided proof-of-concept data supporting the robust capabilities of the platform to identify high-quality antibodies with therapeutic potential.
Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice
March 18, 2022
Speaker: Yi (Benny) Yang, Ph.D. Chief Scientific Officer, Biocytogen Beijing Introduced Biocytogen’s next-generation fully human bispecific antibody development platform, which has facilitated drug discovery for more than two hundred TAA (tumor associated antigen) targets Analyzed the design, screening and drug discovery of bispecific antibodies and bispecific-ADC drugs in two case studies
Mouse Models to Investigate New Treatments for Inflammatory Disease
January 27, 2022
Speaker: Jenna Frame, Ph.D. Manager, Scientific Communications & Marketing, Biocytogen Boston Introduced immune system, cytokines, and autoimmune diseases. Reviewed Modeling Inflammatory Diseases in Wild-Type and Humanized Mice, including multiple Sclerosis/EAE, Rheumatoid Arthritis and Colitis/Inflammatory Bowel Disease. Inflammatory & autoimmune diseases have complex etiologies and mechanisms, but can be modeled in mice. We have established protocols […]
Investigating Inflammatory Disease using Humanized Cytokine Mice
December 2, 2021
Speaker: Clarke Gasper, Ph.D. Senior Business Development Manager, Biocytogen Boston We reviewed the range of cytokines associated with various autoimmune and allergy related diseases. Introduced various humanized cytokine mouse models that can be used in disease modeling. The inflammatory disease models we have developed includes asthma, atopic dermatitis, and psoriasis. Details of some typical readouts […]
Advancing T cell Therapies Using B-hCD3 Mouse Models
November 4, 2021
Biocytogen’s humanized mice are rigorously designed and validated in the following ways to improve translation of CD3-targeting candidates: Expression (mRNA & flow cytometry), Immune cell frequency & maturation profiling and functional validation using reference antibodies whenever available.
Genome Engineering in Accelerating Discovery and Preclinical Applications
September 27, 2021
Use of Biocytogen’s CRISPR-based Extreme Genome Editing technology improves the efficiency of large fragment knock-in by up to 10-20 fold, meaning we can generate targeted cell lines, mouse and rat models in industry-leading timelines with a 98% success rate.
4th Annual Next Gen Immuno-Oncology Virtual Congress: Humanized Immune Checkpoint Mice Improve Translatability of Novel Immunotherapies
July 9, 2021
Biocytogen’s humanized CD3E & CD3EDG models allow for broader targeting of the entire CD3 complex with novel mono- & bispecific antibody therapeutics.
AET Europe 2021: Powerful Engine for Therapeutic Antibody Discovery – RenMab/RenLite Immunoglobulin Humanized Mouse Platform
June 17, 2021
Learn more about Biocytogen’s established first and second generation of immunoglobulin humanized mouse platforms: RenMab and RenLite.
FcRn Therapies 2021 Conference: Humanized Mouse Models to Assess the In Vivo Efficacy of Antibody Therapeutics
March 25, 2021
Learn about the powerful models of Humanized mouse in IL4/IL4RA and IL-17 mice in various in-vivo settings
